1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Paxman AB (publ)

Paxman AB (publ)

PAX.ST
Paxman AB (publ)SE flagStockholm Stock Exchange
48.50
SEK
-0.60
- -
1.13BMarket Cap
Paxman AB (publ)
PAX.ST
(Stockholm Stock Exchange)

Recent

price

48.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.64
3.62
5.33
4.87
5.51
7.67
11.05
13.31
13.46
14.77
Revenue per Share
-0.57
-0.44
0.17
-1.2
-0.73
-0.54
0.44
2.11
-0.72
-0.47
Basic EPS, GAAP
-1.65
-1.14
-1.09
-0.92
-1.6
-1.74
-0.51
0.81
-0.69
-1.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.78
0.56
1.17
-0.2
0.36
0.46
1.44
3.11
0.28
- -
Book Value per Share
1.95
0.97
1
-0.1
6.26
4.81
4.65
6.58
9.01
9.59
Tangible Book Value per Share
12
16
16
16
17
19
19
19
23
23
Basic Weighted Avg Shares
31
58
85
78
96
146
210
253
313
336
Sales/Revenue/Turnover
-21.69
-8.24
-6.99
-14.98
-11
-0.85
6.01
13.24
1.36
-0.39
Operating Margin (%)
2
5
8
11
13
17
19
16
24
30
Depreciation Expense
-7
-7
3
-19
-13
-10
8
40
-17
-11
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
3.14
- -
- -
Effective Tax Rate (%)
-21.46
-12.24
3.23
-24.58
-13.28
-7.08
3.96
15.89
-5.33
-3.2
Profit Margin (%)
13
-8
-10
-20
74
42
44
75
167
176
Working Capital
- -
- -
14
16
6
4
3
1
3
4
LT Debt
33
25
28
11
126
114
123
164
405
409
Total Equity
- -
- -
- -
- -
- -
- -
- -
20.56
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
72.21
- -
- -
Return on Capital (%)
- -
-78.04
19.91
- -
- -
-138.35
46.24
92.89
-50.83
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
7
10
1
LT Borrowings
3
3
4
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
1,508
1,221
1,091

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
235
223
226
Cash, Cash Equivalents & STI
130
121
106
Accounts Receivable, Net
72
46
81
Inventories
30
33
37
Total Current Liabilities
50
56
50
Payables & Accruals
- -
- -
- -
ST Debt
7
10
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
246.77%
147.06%
Free Cash Flow
- -
-85.4%
-204.46%
Net Income, GAAP
- -
1.54%
-141.58%
Sales/Revenue/Turnover
- -
32.64%
23.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
59
63
65
66
253
2025
67
75
87
84
313
2026
90
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.69
0.52
0.26
0.64
2.11
2025
-0.29
-0.14
0.06
-0.38
-0.72
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Electromed, Inc. (ELMD)
Gaush Meditech Ltd (2407.HK)
SHL Telemedicine Ltd. (0QMX.L)
AViTA Corporation (4735.TWO)
Luxbright AB (publ) (LXB.ST)
Dynatronics Corporation (DYNT)
Business
Paxman AB (publ) develops and sells scalp cooling systems to minimize hair loss during chemotherapy treatment; its core product, the Paxman Scalp Cooler, is a mobile electric cooling unit with silicone hats for one or two patients, featuring a touch-screen interface for monitoring; the company also offers single-patient-use cooling caps, insurance-based billing models, and patient assistance programs, with development underway for a device to prevent chemotherapy-induced peripheral neuropathy (CIPN) and collaborations including wearable cooling devices with the University of Huddersfield and University of Leeds, and cooling-compression systems with the National University Hospital of Singapore. Paxman AB (publ) operates worldwide, serving cancer centers and hospitals in primary markets such as Great Britain, Scandinavia, the Netherlands, Belgium, Australia, the United States, and Canada; it targets oncology patients through recurring treatment revenue models, equipment sales, rentals, and regional technician services. Founded in 1996 and headquartered in Karlshamn, Sweden, the company listed on Nasdaq Stockholm under ticker PAX.ST employs approximately 140 people and following its May 2025 acquisition of competitor Dignitana AB (publ) via a public offer valued at SEK 153 million, now integrates the DigniCap system into its portfolio, enhancing US market presence; in March 2025, it raised SEK 123.5 million through a directed share issue to institutional investors including Eiffel Investment Group and Unionen, funding growth including CIPN commercialization, R&D, and a new Huddersfield, UK manufacturing facility by end-2026; recent developments include new Category I CPT codes effective January 2026 for US reimbursement, CMS proposed rates for 2026, and presentation of CIPN trial data at ESMO 2025.